1. Introduction
===============

As one of commonly used sedative drugs for intravenous administration, propofol featured its rapid onset, short duration, and reasonable recovery. However, the pain emerged during the iv infusion of propofol was experienced by up to 85% of pediatric patients,^\[[@R1]\]^ and the induction was considered as one of the most painful stages during perioperative period. Additionally, owing to the small veins of children, the high incidence of propofol injection pain was associated with the high risk during pediatric anesthesia induction. Thus, alleviating the injection pain was considered as a thorny problem needs to be solved.

Various approaches have been tried out to alleviate propofol injection pain, such as adjustment of the temperature of infusion,^\[[@R2]\]^ pretreatment with different medications including opiates, and local anesthetics at varying dosages. Nyman et al^\[[@R3]\]^ tried to premix etomidate with propofol, and Lembert et al^\[[@R4]\]^ chose the nitrous oxide as the medication. In fact, the confirmed effect and reasonable results have been reported with the intravenous administration of ketamine,^\[[@R5]\]^ alfentanil,^\[[@R6]\]^ newer propofol formulation (dissolved in a mixture of medium- and long-chain triglycerides \[MCT/LCT\]),^\[[@R7],[@R8]\]^ and especially lidocaine^\[[@R9],[@R10]\]^ in adult patients.

However, in contrast of the proved efficacy of using lidocaine and other pharmacological interventions in published systematic reviews about adult patients,^\[[@R11]--[@R13]\]^ the relevant systematic review about the efficacy and safety in reducing injection pain of propofol between lidocaine and other medications in pediatric patients has not been established.

In order to evaluate the effects of adjunctive lidocaine and other medications administration on alleviating the propofol injection pain occurred in pediatric patients, the present meta-analysis was performed by aggregating the published randomized controlled trials (RCTs) comparing lidocaine and other frequently used pharmacological approaches in clinic. Moreover, the safety of these medications was also described.

2. Methods
==========

Ethical approval and patient written informed consent are not required due to that this is a systematic review and meta-analysis of previously published studies. This meta-analysis was performed in accordance with the recommendations in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement^\[[@R14]\]^ and the guidelines described in the Cochrane Handbook.

2.1. Inclusion and exclusion criteria
-------------------------------------

### 2.1.1. Participants

The patients were the children (less than 18 years old) with American Society of Anesthesiologists (ASA) physical status I or ASA II. And the types of patients included the children who experienced the propofol induction in different surgeries, diagnostic procedures, and outpatient treatment.

### 2.1.2. Interventions and comparisons

All studies that administered lidocaine intravenously for preventing pain on propofol injection were included. Comparisons included lidocaine versus saline control, lidocaine versus ketamine, lidocaine versus alfentanil, and lidocaine versus propofol lipuro (MCT/LCT).

### 2.1.3. Outcome measurements

Because of inconsistent pain scores used in these published literatures, the primary outcome was the number of patients reporting any pain (incidence of injection pain emergence); if the measurement scores among different studies were similar, the severity of pain (the incidence of propofol injection pain in different degrees) would also be evaluated. Moreover, the description of cardiorespiratory parameters or adverse events would be reviewed to evaluate the safety of the intervention if the enrolled clinical studies mentioned.

### 2.1.4. Studies

In consideration of the quality of literature, all RCTs published in English were included. Trials were excluded if the patients were adult, the medication administrated was not involving lidocaine, and data from the case reports, reviews, and the animal studies.

### 2.1.5. Search strategy

The literature search for published RCTs was conducted by 2 reviewers (BL and CY), and the databases included PubMed, Embase, and the Cochrane Library. The following search terms: "injection pain," propofol, lidocaine, pediatrics, adolescent, teenager, child, infant, children, preschool, kids were combined using "and" or "or" for searching for relevant studies. The search was restricted to human studies and the language of publications was restricted to English. The last literature search was performed in May 31, 2016.

### 2.1.6. Data extraction

All data were extracted by BL and CY independently. After screening of the titles and abstracts, full articles were obtained when information could not be ascertained. The information derived from literatures was collected and entered into a table which included the following contents: the general characteristics of studies, the types and general characteristics of patients, the sample size, and interventions and comparisons (Table [1](#T1){ref-type="table"}). The disagreements were resolved by consensus through discussion among all authors.

###### 

The general characteristics of the enrolled studies.
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### 2.1.7. Quality assessment

BL and CY independently evaluated the methodological quality of included studies by using the Cochrane Collaboration tool for assessing risk of bias in randomized trials.^\[[@R15]\]^ There are 7 items to assess random sequence generation including allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias using high, low, or unclear risk of bias.^\[[@R16]\]^

2.2. Statistics analysis
------------------------

All statistical analyses were performed using the Review Manager 5.0 software. Dichotomous data were analyzed by using the risk ratio (RR) with 95% confidence intervals, the Mantel Haenszel method (fixed or random models). I-square (*I*^2^) test was performed to assess the impact of study heterogeneity on the results of the meta-analysis. According to the Cochrane review guidelines, if severe heterogeneity was present at *I*^2^ \> 50%, the random effect models were chosen, otherwise the fixed effect models were used. If interventions involved 10 or more studies, the tunnel plots were used to visualize the reporting bias. Moreover, sensitivity analysis was conducted by deleting each study individually to evaluate the quality and consistency of the results.

3. Results
==========

After search of the database mentioned above, 38 articles were identified by initial screening. Following the full-text review, 11 articles published in English were enrolled in the present systematic review.^\[[@R17]--[@R27]\]^ The identification procedure of these eligible articles is described in Fig. [1](#F1){ref-type="fig"}. The studies from different regions were published from 1992 to 2013. The child age ranged from 2 months to 18 years. In these studies, the incidence of propofol injection pain was reported in 9 of them,^\[[@R17]--[@R23],[@R25],[@R27]\]^ and the number of patients experienced injection pain in different degrees was reported in 6 of them.^\[[@R18],[@R20]--[@R23],[@R25]\]^ Normal saline was used as the control in 4 studies,^\[[@R18],[@R19],[@R21],[@R23]\]^ ketamine was used as the comparison in 2 studies,^\[[@R20],[@R25]\]^ alfentanil was used as the comparison in 3 studies,^\[[@R17],[@R18],[@R22]\]^ and propofol lipuro (MCT/LCT) was used as the comparison in 2 studies.^\[[@R19],[@R27]\]^ The grade measuring injection pain severity was selected inconsistently, 4-point scale was chosen in 6 studies, 3-point scale was used in 2 studies, and 0--6 graded scale, FLACC Scale, and mCHEOPS were used in 1 study, respectively. The general characteristics of the enrolled characters are shown in Table [1](#T1){ref-type="table"}.

![Flow chart of literature screening and the selection process.](medi-96-e6320-g002){#F1}

3.1. Quality assessment
-----------------------

According to the Cochrane Collaboration tool for assessing risk of bias, the 7 items including random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias of these including RCTs were evaluated. A total of 73% (8/11) studies used an adequate method of random sequence generation,^\[[@R19]--[@R23],[@R25],[@R27]\]^ 64% (7/11) of the studies mentioned "allocation concealment" with the description of using opaque, sealed envelopes. Three studies^\[[@R18],[@R20],[@R26]\]^ did not mention the blinding procedure of participants and personnel, and only 2 studies^\[[@R20],[@R26]\]^ did not mention the blinding procedure of outcome assessment. The risk of bias assessment tool is shown in Fig. [2](#F2){ref-type="fig"}.

![Risk of bias assessment of included studies.](medi-96-e6320-g003){#F2}

4. Incidence of injection pain associated with propofol induction
=================================================================

4.1. Lidocaine versus saline
----------------------------

A total of 448 pediatric patients were included in the study, and 231 of them were given the lidocaine intravenously to alleviate the pain produced by propofol induction. Compared with the placebo (saline), intravenous administration of lidocaine definitely reduced the incidence of injection pain which was described as the number of pain occurrence (the incidence of pain: 22.1% in lidocaine vs 66.8% in saline, RR with 95% 0.34 \[0.26, 0.43\], *I*^2^ = 38%). The *I*^2^ of 38% indicated that the substantial heterogeneity was not existed, thus the fixed effect model was used. The result is shown in Fig. [3](#F3){ref-type="fig"}.

![Effect of lidocaine versus saline control in reducing the incidence of propofol injection pain.](medi-96-e6320-g004){#F3}

4.2. Lidocaine versus ketamine
------------------------------

The study included a total of 238 pediatric patients, and 118 of them were given the lidocaine intravenously to alleviate the injection pain. And the incidence of pain occurrence indicated that there were no difference between the using of lidocaine and the using of ketamine (the incidence of pain: 29.7% in lidocaine vs 25.8% in ketamine, RR with 95% 1.47 \[0.16, 13.43\], *I*^2^ = 94%). The heterogeneity was substantial and the number of studies was limited, and the random effect was used. The result is shown in Fig. [4](#F4){ref-type="fig"}.

![Effect of lidocaine versus ketamine in reducing the incidence of propofol injection pain.](medi-96-e6320-g005){#F4}

4.3. Lidocaine versus alfentanil
--------------------------------

The study included a total of 230 pediatric patients, and 116 of them were given the lidocaine intravenously. The incidence of pain occurrence indicated that there were no difference between the using of lidocaine and alfentanil (the incidence of pain: 31.0% in lidocaine vs 30.7% in alfentanil, RR with 95% 1.01 \[0.69, 1.46\], *I*^2^ = 11%). The *I*^2^ of 11% indicated that the substantial heterogeneity was not existed, thus the fixed effect model was used. The result is shown in Fig. [5](#F5){ref-type="fig"}.

![Effect of lidocaine versus alfentanil in reducing the incidence of propofol injection pain.](medi-96-e6320-g006){#F5}

4.4. Lidocaine versus propofol lipuro (MCT/LCT)
-----------------------------------------------

A total of 163 pediatric patients were included in the study, and 82 of them were given the lidocaine intravenously to alleviate the pain. Compared with the propofol lipuro (MCT/LCT), intravenous administration of lidocaine had the efficiency in reducing injection pain (the incidence of pain: 30.5% in lidocaine vs 46.9% in propofol lipuro, RR with 95% 0.68 \[0.46, 1.00\], *I*^2^ = 9%). The *I*^2^ of 9% indicated that the heterogeneity was not existed, thus the fixed effect model was used. The result is shown in Fig. [6](#F6){ref-type="fig"}.

![Effect of lidocaine versus propofol lipuro (MCT/LCT) in reducing the incidence of propofol injection pain. MCT/LCT = medium- and long-chain triglycerides.](medi-96-e6320-g007){#F6}

5. Severity of injection pain associated with propofol induction
================================================================

Considered as the inconsistent score/grade used in measuring the severity of pain among pediatric patients in these included studies, the number of pediatric patients who experienced slight, moderate, and the severe pain was reviewed respectively to evaluate the severity of injection pain when the similar pain measurement was used between the different studies.

5.1. Lidocaine versus saline
----------------------------

A 4-point scale was used in 3 of the studies, and the score 2, score 3, and score 4 symbolized slight, moderate, and severe pain individually. Compared with the placebo (saline), the incidence of moderate and severe pain occurred in pediatric patients who received intravenous administration of lidocaine was significantly lower (the incidence of severe pain: 1.58% in lidocaine vs 15.64% in saline control, RR with 95% 0.12 \[0.04, 0.35\], *I*^2^ = 0%; the incidence of moderate pain: 6.84% in lidocaine vs 31.84%, RR with 95% 0.24 \[0.10, 0.54\], *I*^2^ = 50%), and the difference of occurrence rate of slight pain in between lidocaine group and control group was not significant (the incidence of slight pain: 13.68% in lidocaine vs 21.23% in saline, RR with 95% 0.65 \[0.42, 1.03\], *I*^2^ = 0%). The *I*^2^ of 0% indicated that the heterogeneity was not existed, thus the fixed effect model was used, while the *I*^2^ of 50% indicated that the heterogeneity was existed, the random effect model was chosen. The details are shown in Figs. [7](#F7){ref-type="fig"}--[9](#F9){ref-type="fig"}.

![The incidence of severe pain in group lidocaine versus group saline control.](medi-96-e6320-g008){#F7}

![The incidence of moderate pain in group lidocaine versus group saline control.](medi-96-e6320-g009){#F8}

![The incidence of slight pain in group lidocaine versus group saline control.](medi-96-e6320-g010){#F9}

5.2. Lidocaine versus ketamine
------------------------------

A 3-point scale was used in the 2 studies, and the high-grade pain was defined as score 3, the moderate-grade pain was defined as score 2. The incidence of both high-grade pain and moderate pain occurrence indicated that there were no difference between the using of lidocaine and the using of ketamine (the incidence of severe pain: 10.2% in lidocaine vs 25.8% in ketamine, RR with 95% 2.16 \[0.03, 176.34\], *I*^2^ = 88%; the incidence of moderate pain: 19.49% in lidocaine vs 18.33% in ketamine, RR with 95% 1.21 \[0.27, 5.39\], *I*^2^ = 84%). However, the heterogeneity was substantial, and the limited number of involving studies showed the unreliability of the result (Figs. [10](#F10){ref-type="fig"} and [11](#F11){ref-type="fig"}).
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5.3. Lidocaine versus alfentanil
--------------------------------

A 4-point scale was used in 2 of the studies. The incidence of severe pain, moderate pain, and slight pain occurrence indicated that there were no difference between the using of lidocaine and alfentanil (the incidence of severe pain: 3.3% in lidocaine vs 5.6% in alfentanil, RR with 95% 0.58 \[0.14, 2.37\], *I*^2^ = 0%; the incidence of moderate pain: 11.0% in lidocaine vs 6.7% in alfentanil, RR with 95% 1.61 \[0.61, 4.21\], *I*^2^ = 10%; the incidence of slight pain: 24.2% in lidocaine vs 22.5% in alfentanil, RR with 95% 1.08 \[0.63, 1.83\], *I*^2^ = 0%). The *I*^2^ of 0% and 10% indicated that the heterogeneity was not existed, thus the fixed effect model was used. The result is shown in Figs. [12](#F12){ref-type="fig"}--[14](#F14){ref-type="fig"}.
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![The incidence of slight pain in group lidocaine versus group alfentanil.](medi-96-e6320-g015){#F14}

6. The side effects
===================

A total of 8 studies^\[[@R11],[@R13],[@R14],[@R16],[@R17]--[@R25]\]^ mentioned the side effects occurred during the anesthesia. The reported side effects in literatures were sporadic and diverse, thus we tried to describe the details of them (Table [2](#T2){ref-type="table"}). According to the records, the mean heart rate and mean arterial pressure from most of patients receiving lidocaine intravenously were maintained within normal limit, and there was no hypotension or bradycardia during the study period. None of the patients suffered from hypoxemia, desaturation, apnea, and chest wall rigidity during the induction of anesthesia. However, 1 child received lidocaine^\[[@R25]\]^ and 1 child received ketamine^\[[@R20]\]^ developed laryngospasm. Especially, iv premedication with lidocaine injected at a dose of 2 mg/kg frequently induced bouts of coughing in infants.^\[[@R21]\]^ And benign cutaneous rashes occurred in 3 pediatric patients (2 received propofol--saline and 1 received propofol lipuro \[MCT/LCT\]--saline).^\[[@R19]\]^ And the transient severe bradycardia (heart rate fall more than 50% from the preceding value) occurred in 2 children and junctional rhythm occurred in 7 children who received the alfentanil.^\[[@R17]\]^

###### 

The description of side effects occurred in included studies.
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7. Discussion
=============

Our study indicated that intravenous administration of lidocaine should be a reasonable approach to alleviate propofol injection pain occurred in pediatric patients. Especially in comparison to the controlled medicine such as ketamine and alfentanil, lidocaine would be served as one more effective treatment in consideration of its well-matched efficacy, acceptable accessibility, and reasonable safety.

Injection pain was always deemed as one common but thorny problem during propofol induction, and it was ranked 7th in 33 outcomes of clinical anesthesia by expert anesthesiologists,^\[[@R28]\]^ according to the frequency they believe that the outcomes occurrence and the importance they expect patients to understand. To increase quality of clinical anesthesia and treatment, reducing the incidence and severity of the top items should be prioritized. However, the potential mechanism of the injection pain associated with the using of propofol was still unclear. The insolubility and the application of emulsion was once thought to be the culprit of the injection pain, thus, the alteration in concentration,^\[[@R29]\]^ infusion rate,^\[[@R30]\]^and the research about the water-soluble propofol prodrugs^\[[@R31]\]^ had been considered by clinical scientists. Actually, it should be admitted that the pharmacological interventions played an important role in reducing the propofol injection pain in current clinical anesthesia. However, to our knowledge, about the comparison of efficacy and safety between these pharmacological interventions, no information is available in children. And our study firstly reviewed the studies about these drugs which were used frequently in clinical anesthesia.

The literature screening in our present study was strictly followed the thorough strategies and inclusion criteria. To comprehensively evaluate the practical clinical value of using lidocaine, the randomized controlled studies performed in pediatric patients about comparison including lidocaine versus ketamine, lidocaine versus alfentanil, and lidocaine versus MCT/LCT propofol were enrolled in the present study.

And the risk of bias assessment tool devised by the Cochrane Collaboration showed that 11 studies included were at different risk. And we also found that inconsistency of reported outcome existed in these studies. The incidence of injection pain associated with the using of propofol did not report in 2 studies,^\[[@R24],[@R26]\]^ and the measurement scores of pain severity among these trials were varied including 3-point scale, 4-point scale, and 6-point scale, etc. Therefore, our study reviewed the trials used the same pain score, and collected the number of pediatric patients who experienced different grade pain to evaluate the efficacy of using lidocaine and other medications in alleviating the severity of injection pain.

As same as the previous reports in adult patients, the results indicated that the using of lidocaine intravenously had confirmed effect in alleviating the injection pain both in incidence and the severity (especially the severe pain and the moderate pain) in pediatric patients (Figs. [3](#F3){ref-type="fig"}, [7](#F7){ref-type="fig"}, [8](#F8){ref-type="fig"}). Although the published literatures have been reported that the application of propofol lipuro (MCT/LCT) was effective in reducing the injection pain, the present study indicated that the using of lidocaine exhibited existed but not obvious superiority in solving the problem (Fig. [6](#F6){ref-type="fig"}).

And there was no difference in reducing pain incidence and pain severity between lidocaine and ketamine/alfentanil. Thereinto, in view of the factor about drug regulation, the iv administration of lidocaine should be the reasonable and convenient option for its accessibility and affordability. However, it was worth noting that the substantial heterogeneity in the comparison between lidocaine and ketamine would affect the reliability of the outcome. And it may be derived from the opposite conclusion of the only 2 RCTs;^\[[@R20],[@R25]\]^ therefore, more evidence with high quality would be necessary to determine which was the preferred option in reducing the injection pain in children.

In addition, our study also provides the findings about the safety of the using of lidocaine, ketamine, alfentanil, and propofol lipuro (MCT/LCT). The results from the existing trials indicated that the specific cases of side effect cases occurred in vary degrees including coughing, laryngospasm, and even transient severe bradycardia. However, there was insufficient evidence currently to presume the complete safety of these different pharmacological interventions. By contrast, lidocaine seemed more applicable, especially considered as the coughing before anesthesia induction is advantageous in infants and children as it clears secretions from the upper airway.^\[[@R21]\]^

Overall, the comparatively determinate conclusion was that the application of lidocaine intravenously should be considered as one promising approach in decreasing the injection pain occurred in pediatric patients from many different perspectives including efficiency, safety, and resource availability. The limitation of our study was the limited numbers of the RCTs performed in children. Given that the actual effects and the clinical application value of such intervention in pediatric anesthesia should be evaluated in depth, more high-quality evidences in pediatrics are necessary.
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